Chemokine-based therapies for MS: how do we get there from here?
The workshop on Multiple Sclerosis and Chemokines: Prospects for Therapeutic and Prophylactic Intervention was held in Chevy Chase, MD, USA, from 9-10 July 2001.
Kivisäkk
P
P
Dept of Neurosciences, The Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Trebst
C
C
Eckstein
D J
DJ
Kerza-Kwiatecki
A P
AP
Ransohoff
R M
RM
D016564:Amyloid beta-Protein Precursor / Q000031:analogs & derivatives* / Q000378:metabolism; D000818:Animals; D002490:Central Nervous System / Q000276:immunology / Q000473:pathology; D018925:Chemokines / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D007962:Leukocytes / Q000276:immunology; D009103:Multiple Sclerosis / Q000276:immunology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D019707:Receptors, Chemokine / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
C489697:APLP1 protein, human; D016564:Amyloid beta-Protein Precursor; D018925:Chemokines; D019707:Receptors, Chemokine